HIV Infections Clinical Trial
Official title:
Imaging Immune Activation in HIV Infection
This is a single center exploratory imaging study involving one intravenous microdose of [18F]F-AraG followed by whole-body positron emission tomography-magnetic resonance (PET-MR) imaging in HIV infected individuals to determine the anatomical distribution of the PET tracer. Participants will be enrolled if they were treated during early or late HIV infection. In addition, individuals not on antiretroviral therapy (ART) or with HIV-1 plasma RNA levels >5,000 copies/mL will be enrolled.
The PET radiofluorinated imaging agent, [18F]F-AraG
(2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine; trade name VisAcT) localizes to sites of
immune activation and is predominantly accumulated in proliferative T cells. As a result,
there is interest in imaging residual immune activation in the setting of both treated and
untreated HIV-1 infection, a disease in which chronic immune activation and inflammation may
lead to significant morbidity, despite the use of otherwise suppressive ART.
The primary endpoint is to determine the anatomical distribution of [18F]F-AraG in
HIV-infected individuals taking or not taking antiretroviral therapy.
Secondary objectives are to determine if [18F]F-AraG PET-MRI is able to detect differences in
T cell activation between patients with early versus late treated HIV infection and to
determine if [18F]F-AraG uptake correlates with direct blood and tissue measures of HIV
reservoir size and activity in the above cohorts/studies.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Recruiting |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Enrolling by invitation |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 | |
Completed |
NCT01968551 -
Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults
|
Phase 3 | |
Recruiting |
NCT03701802 -
Immunogenetic Modulators of Mucosal Protection From HIV-1
|
||
Recruiting |
NCT03271307 -
Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners
|
N/A | |
Recruiting |
NCT03577782 -
Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral Therapy
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01937455 -
A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.
|
Phase 1 | |
Active, not recruiting |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Withdrawn |
NCT01975012 -
Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01931358 -
Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E
|
Phase 2 | |
Completed |
NCT01923610 -
Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B
|
Phase 1 | |
Recruiting |
NCT01439503 -
Safer Sex Program for Young African-American Men
|
Phase 2 | |
Terminated |
NCT01583439 -
The Mochudi Prevention Project ART Protocol
|
N/A |